Dapagliflozin-Metformin in the Diabetes Care Continuum: When to Consider?- Dr Praveen G

Combination Therapy-Pillars in Diabetes Care Continuum

Type 2 diabetes mellitus (T2DM) represents a significant and escalating health challenge, particularly in low- and middle-income countries (LMICs), including India [1]. T2DM generally doubles the risk of vascular outcomes, including coronary artery disease, ischemic stroke, and vascular death, independent of other risk factors [2]. The increasing burden of diabetes-related complications, such as cardiovascular diseases (CVDs), necessitates a personalized approach to enhance treatment compliance [1]. Clinical practice guidelines, including the most recent 2026 American Diabetes Association (ADA) Standards of Care in Diabetes, advocate for early combination therapy for patients with T2DM, as it facilitates faster achievement of glycemic goals and ensures longer durability of the glycemic effect [3, 4].

Optimising T2D Care: Beyond HbA1c to Complications Outcomes

While achieving glycemic control remains fundamental to T2DM management, evidence indicates that reducing glycated hemoglobin (HbA1c) alone is insufficient to fully mitigate long-term cardiovascular (CV) risks. Although elevated HbA1c levels are consistently linked to adverse CV outcomes, intensive glucose lowering has not uniformly resulted in proportional reductions in CV events, particularly in patients with established CVDs. Conversely, CV outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly reduce heart failure (HF), chronic kidney disease (CKD) progression, and CV events beyond their glucose-lowering effects [5].

Recently, the updated National Institute for Health and Care Excellence (NICE) 2026 guidelines recommended the early use of SGLT2 inhibitors alongside metformin in most adults with T2DM, recognizing their CV benefits beyond glycemic control (Fig 1) [6].

Dapagliflozin & Metformin- Promising Strategy for Managing T2DM with Organ Protection

The combination of dapagliflozin + metformin addresses multiple pathophysiological defects through complementary mechanisms. Metformin primarily suppresses hepatic glucose production and improves insulin sensitivity, whereas dapagliflozin lowers plasma glucose levels by inhibiting renal glucose reabsorption via SGLT2 receptors, resulting in insulin-independent urinary glucose excretion. Beyond glycemic control, dapagliflozin exerts favorable effects on body weight, blood pressure (BP), cardiac preload and afterload, and intraglomerular hemodynamics, translating into clinically meaningful CV and renal protection, making the combination a rational strategy for comprehensive T2DM management beyond glucose lowering [7,8].

A randomized controlled trial (RCT) published in 2026 involving treatment-naïve patients with T2DM demonstrated that first-line therapy with dapagliflozin + metformin resulted in superior glycemic control. Additionally, this combination therapy improved endothelial function and reduced markers of pro-inflammatory sphingolipids and oxidative stress compared to monotherapy. These findings suggest that dapagliflozin + metformin combination therapy provides vasculo-protective and cardio-protective benefits beyond blood glucose control [9].

Dapagliflozin & Metformin Combination in T2D: When to Consider?

Newly Diagnosed Treatment-naïve T2D patients:

In treatment-naïve patients with T2DM (baseline HbA1c 7.5–9%), initial combination therapy with dapagliflozin + metformin reduced HbA1c by 1.98-2.05% from baseline, compared with 1.19-1.45% with dapagliflozin alone and 1.35-1.44% with metformin monotherapy (P<0.0001). Dapagliflozin + metformin combination therapy also produced greater reductions in fasting plasma glucose (FPG) and body weight while maintaining a favorable tolerability profile [10].

T2DM Patients with Metabolic Syndrome

In a recent RCT, the combination of dapagliflozin + metformin demonstrated superior improvements across multiple components of metabolic syndrome, including greater reductions in body weight, body mass index (BMI), waist circumference, FPG, and triglyceride levels. After a one-year intervention, remission of metabolic syndrome was observed in 76.6% of patients in the dapagliflozin + metformin treatment group. This combination also led to improvements in insulin resistance, fasting plasma insulin levels, and inflammatory biomarkers, increase in high density lipoprotein (HDL)-cholesterol, and reductions in both systolic and diastolic BP, indicating its extensive cardio-metabolic benefits beyond glycaemic control [11].

T2D with High CV risk

In the DECLARE–TIMI 58trial, which included 17,160 patients (59.4% with multiple CV risk factors), dapagliflozin reduced the composite of CV death or hospitalization for HF by 17% (Hazard ratio (HR) 0.83; 95% confidence interval (CI) 0.73–0.95), primarily driven by a 27% reduction in hospitalization for HF (HR 0.73; 95% CI 0.61–0.88). These findings support the early addition of dapagliflozin to metformin in patients at high CV risk to provide cardio-renal protection beyond glycaemic control [12].

T2D with High CKD Risk/CKD

A large real-world comparative effectiveness study involving over 36,000 propensity score-matched patients with T2DM demonstrated that SGLT2 inhibitors, including dapagliflozin and empagliflozin, provided comparable renal protection, with no significant difference in the risk of CKD progression (HR 1.08; 95% CI 0.98–1.18), sustained ≥40% decline in estimated glomerular filtration rate (eGFR) (HR 1.07; 95% CI 0.97–1.18), or kidney failure (HR 1.12; 95% CI 0.88–1.42) between the two agents. The DAPA-CKD trial showed a 39% reduction in CKD progression, renal/CV death, together with a 31 % reduction in all-cause mortality [13, 14].

T2DM with Cardiovascular diseases

Across major CVOTs, dapagliflozin consistently demonstrated clinically meaningful reductions in CV and renal event rates. A recent nationwide cohort study of 9,109 Korean patients with T2DM compared dapagliflozin plus metformin with empagliflozin plus metformin and found comparable protection against ischemic CV events, demonstrating a low incidence of myocardial infarction, ischemic stroke, coronary revascularization (adjusted HR 0.50; 95% CI 0.24–1.03), unstable angina, or all-cause mortality, supporting dapagliflozin and metformin as an effective strategy for CV risk reduction [15, 16].

Fig 1: Dapagliflozin & Metformin Combination- Practical Considerations & Potential Benefits across T2DM Care continuum

Figure recreated from ref 7-16

Abbreviations: CV-Cardiovascular, CVD-Cardiovascular diseases, CRM-Cardio-renal-metabolic, CKD=Chronic kidney disease, FPG-Fasting plasma glucose, HbA1C-Glycated hemoglobin, T2DM-Type 2 diabetes mellitus, BMI-Body mass index, HHP-Hospitalization due to heart failure

When to Consider Dapagliflozin plus Metformin Combination? - Expert opinion

In India, experts emphasize that CV risk is a significant concern for patients with T2DM. Therefore, it seems prudent to initiate SGLT2 inhibitors in all T2DM patients with comorbid conditions to reduce the risk of HF, when indicated. Among SGLT2 inhibitors, dapagliflozin along with metformin is noted for its higher potency, broader acceptability, and substantial evidence base [17].

Final Practice Point of View (PoV)

•  The management of T2DM in real-world clinical practice should simultaneously address glycemic control, CVD and CKD progression, and overall metabolic health.
•  Initiating early evidence-based combination therapy, such as dapagliflozin and metformin, delays disease progression and reduces long-term complications, supporting a proactive treatment strategy.
•  T2DM patients with obesity, metabolic syndrome, and CVD or CKD risk may experience additional benefits from dapagliflozin and metformin therapy owing to its complementary actions beyond glycemic control.
•  Combining evidence-based therapy with lifestyle practices is encouraged to maximize long-term glycaemic, CV, and renal benefits through follow-up and patient education.